PMID- 36751540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230209
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 38
IP  - 2
DP  - 2021 Apr
TI  - Comparing the efficacy and safety of IL-17 inhibitors for treatment of 
      moderate-to-severe psoriasis: a randomized double blind pilot study with a review 
      of literature.
PG  - 281-288
LID - 10.5114/ada.2019.91496 [doi]
AB  - INTRODUCTION: Psoriasis is a chronic skin disease in which interleukin-17A 
      (IL-17A) has been found to play an important role. Commercially available 
      anti-IL-17 drugs include brodalumab, ixekizumab (IXE), and secukinumab (SEC). 
      AIM: To compare the safety and efficacy of IXE and SEC in patients with 
      moderate-to-severe plaque psoriasis. MATERIAL AND METHODS: The patients were 
      randomized to the IXE or SEC group. Effectiveness was estimated by Physician's 
      Global Assessment (PGA), Psoriasis Area and Severity Index (PASI), and 
      Dermatology Life Quality Index (DLQI). Safety was assessed by documentation of 
      adverse effects (AEs), routine laboratory values, and injection-site and allergic 
      reactions. RESULTS: There were 155 patients in the IXE group and 158 in the SEC 
      group. At week 12, PASI 75 was 76.77% (IXE) vs. 67.09% (SEC); PASI 90 42.58% 
      (IXE) vs. 32.28% (SEC); PGA score of 0 or 1 at week 40 (79.52% vs. 74.4%) and at 
      week 52 (61.83% vs. 58.12%) (p < 0.001). Also, DLQI score improvement was more 
      pronounced in the IXE group. The rates and types of AEs were similar in both 
      groups. CONCLUSIONS: Although both groups demonstrated a robust clinical 
      response, a significant improvement in patient quality of life, and a 
      satisfactory safety profile, the IXE group scored a notch higher.
CI  - Copyright (c) 2022 Termedia.
FAU - AlMutairi, Nawaf
AU  - AlMutairi N
AD  - Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait.
FAU - Eassa, Bayoumy Ibrahim
AU  - Eassa BI
AD  - Department of Dermatology, Farwaniya Hospital, Kuwait.
LA  - eng
PT  - Journal Article
DEP - 20200109
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC9880774
OTO - NOTNLM
OT  - IL-17 inhibitors
OT  - ixekizumab
OT  - plaque psoriasis
OT  - secukinumab
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/01 00:00
MHDA- 2021/04/01 00:01
PMCR- 2021/04/01
CRDT- 2023/02/08 01:58
PHST- 2019/10/18 00:00 [received]
PHST- 2019/11/18 00:00 [accepted]
PHST- 2023/02/08 01:58 [entrez]
PHST- 2021/04/01 00:00 [pubmed]
PHST- 2021/04/01 00:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 39535 [pii]
AID - 10.5114/ada.2019.91496 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2021 Apr;38(2):281-288. doi: 10.5114/ada.2019.91496. 
      Epub 2020 Jan 9.